Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Conditions
Interventions
Temozolomide
Locations
4
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
University of Miami
Miami, Florida, United States
Oregon Health & Science University
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
September 12, 2018
Primary Completion Date
June 1, 2025
Completion Date
June 1, 2026
Last Updated
November 4, 2024
NCT07434843
NCT05957367
NCT03594422
NCT06326346
NCT05493215
NCT03050268
Lead Sponsor
Adam Burgoyne, MD, PhD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions